Importantly, none of these cells (non-malignant or non-GBM cancers) exhibited either reduced RRM2 protein levels or S-phase arrest, thereby indicating a unique mechanism used by GBM cells for protection to supra-physiological levels of RS. This evidence concerns the gene RRM2 and cancer.